Literature DB >> 16596001

Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate.

Fumiko Tanaka1, Atsushi Kawakami, Nozomi Iwanaga, Mami Tamai, Yasumori Izumi, Kouichiro Aratake, Kazuhiko Arima, Makoto Kamachi, Hideki Nakamura, Mingguo Huang, Hiroaki Ida, Tomoki Origuchi, Katsumi Eguchi.   

Abstract

We have experienced a Takayasu arteritis (TA) patient, successfully treated with infliximab, who did not respond well to conventional therapy with glucocosteroid and methotrexate. Takayasu arteritis had developed in a 24-year-old woman (March 2003) who had been treated with glucocorticoid including methylprednisolone pulse therapy and methotrexate; however, she relapsed during the tapering of the dosage of oral prednisolone. Nineteen months after the first administration of glucocorticoid, 3 mg/kg of infliximab was introduced to the patient. The therapeutic efficacy of infliximab was markedly demonstrated; the patient's C-reactive protein (CRP) value returned to almost normal range with subsequent tapering of the dosage of oral prednisolone in the absence of further relapse. This is the first case presentation of TA in Japan successfully treated with infliximab.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596001     DOI: 10.2169/internalmedicine.45.1377

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  13 in total

Review 1.  Renovascular hypertension--is it fibromuscular dysplasia or Takayasu arteritis.

Authors:  Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2012-03-28       Impact factor: 3.714

2.  Novel strategy for the treatment of refractory vasculitis syndrome.

Authors:  Hidehiro Yamada
Journal:  Ann Vasc Dis       Date:  2013-02-15

3.  Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-α: a randomized placebo-controlled double-blind clinical trial.

Authors:  Nan Shao; Huixin Jia; Yiwen Li; Jingying Li
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

4.  A case of Crohn's disease associated with Takayasu's arteritis and Henoch-Schönlein purpura.

Authors:  Kotaro Ogawa; Takayuki Matsumoto; Shinichiro Yada; Atsushi Hirano; Yoshiteru Kumagae; Kenichi Goto; Kazunori Urabe; Mitsuo Iida
Journal:  Clin J Gastroenterol       Date:  2009-02-17

Review 5.  Advances in the use of biologic agents for the treatment of systemic vasculitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

6.  [Vasculitis and hereditary small vessel diseases].

Authors:  C Opherk; N Peters; M Dichgans
Journal:  Internist (Berl)       Date:  2009-11       Impact factor: 0.743

Review 7.  Large vessel vasculitis.

Authors:  Ashima Gulati; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2009-10-17       Impact factor: 3.714

8.  Infliximab therapy in pediatric Takayasu's arteritis: report of two cases.

Authors:  Paola Sabrina Buonuomo; Claudia Bracaglia; Andrea Campana; Antonella Insalaco; Manuela Pardeo; Elisabetta Cortis; Alberto G Ugazio
Journal:  Rheumatol Int       Date:  2009-10-23       Impact factor: 2.631

9.  Takayasu disease on the centenary of its discovery.

Authors:  Kazuhisa Sugiyama; Shigeyuki Ijiri; Shigeki Tagawa; Koichi Shimizu
Journal:  Jpn J Ophthalmol       Date:  2009-03-31       Impact factor: 2.447

10.  Biologic agents in systemic vasculitis.

Authors:  Charles F Henderson; Philip Seo
Journal:  Int J Clin Rheumtol       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.